Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphangioleiomyomatosis × Imatinib Mesylate × Clear all

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 79 Leukemia 45 Gastrointestinal Stromal Tumors 37 Leukemia, Myeloid, Chronic-Phase 25 Precursor Cell Lymphoblastic Leukemia-Lymphoma 23 Blast Crisis 14 Philadelphia Chromosome 13 Brain Neoplasms 11 Lung Neoplasms 9 Gliosarcoma 9 Glioblastoma 9 Leukemia, Myeloid, Acute 8 Sarcoma 7 Leukemia, Myeloid, Accelerated Phase 7 Glioma 7 Prostatic Neoplasms 6 Oligodendroglioma 6 Neoplasms 6 Neoplasm Metastasis 6 Dermatofibrosarcoma 6 Small Cell Lung Carcinoma 5 Melanoma 5 Central Nervous System Neoplasms 5 Astrocytoma 5 Stomach Neoplasms 4 Recurrence 4 Primary Myelofibrosis 4 Ovarian Neoplasms 4 Leukemia, Myelomonocytic, Chronic 4 Leukemia, Myeloid 4

Interventions

Sirolimus 6 Everolimus 3 saracatinib 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Letrozole 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Doxycycline 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03131999 2020-06-16

LAMP-1

Medical University of South Carolina

Phase 1/2 Completed

18 enrolled 7 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡